Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
Annexon (ANNX) has granted stock options to six new non-executive employees as part of its 2022 Employment Inducement Award Plan. The equity awards, approved on February 10, 2025, comply with Nasdaq Listing Rule 5635(c)(4). The employees received options to purchase a total of 542,000 shares of Annexon common stock at an exercise price of $3.07 per share, matching the closing price on February 14, 2025.
The options have a ten-year term and vest over four years, with 25% vesting after the first year and the remaining vesting monthly at 1/48th, contingent on continued employment.
Annexon (ANNX) ha concesso opzioni su azioni a sei nuovi dipendenti non esecutivi come parte del suo Piano di Incentivazione all'Occupazione 2022. Le assegnazioni azionarie, approvate il 10 febbraio 2025, sono conformi alla Regola di Quotazione Nasdaq 5635(c)(4). I dipendenti hanno ricevuto opzioni per acquistare un totale di 542.000 azioni di azioni ordinarie di Annexon a un prezzo di esercizio di $3,07 per azione, corrispondente al prezzo di chiusura del 14 febbraio 2025.
Le opzioni hanno un termine di dieci anni e maturano in quattro anni, con il 25% che matura dopo il primo anno e il restante che matura mensilmente a 1/48, subordinato al mantenimento dell'impiego.
Annexon (ANNX) ha otorgado opciones sobre acciones a seis nuevos empleados no ejecutivos como parte de su Plan de Incentivo de Empleo 2022. Las concesiones de acciones, aprobadas el 10 de febrero de 2025, cumplen con la Regla de Cotización de Nasdaq 5635(c)(4). Los empleados recibieron opciones para comprar un total de 542,000 acciones de acciones ordinarias de Annexon a un precio de ejercicio de $3.07 por acción, coincidiendo con el precio de cierre del 14 de febrero de 2025.
Las opciones tienen un plazo de diez años y se consolidan durante cuatro años, con el 25% consolidándose después del primer año y el resto consolidándose mensualmente a 1/48, condicionado a la continuidad del empleo.
Annexon (ANNX)는 2022년 고용 유인 상금 계획의 일환으로 여섯 명의 신규 비상임 직원에게 주식 옵션을 부여했습니다. 2025년 2월 10일에 승인된 이 주식 보상은 나스닥 상장 규칙 5635(c)(4)에 부합합니다. 직원들은 Annexon 보통주 542,000주를 주당 $3.07의 행사 가격으로 구매할 수 있는 옵션을 받았으며, 이는 2025년 2월 14일의 종가와 일치합니다.
이 옵션은 10년의 기간을 가지며 4년에 걸쳐 분할됩니다. 첫 해가 지나면 25%가 분할되고 나머지는 매달 1/48씩 분할되며, 계속 고용되는 조건입니다.
Annexon (ANNX) a accordé des options d'achat d'actions à six nouveaux employés non exécutifs dans le cadre de son Plan d'Attribution d'Emploi 2022. Les attributions d'actions, approuvées le 10 février 2025, sont conformes à la Règle d'Inscription Nasdaq 5635(c)(4). Les employés ont reçu des options pour acheter un total de 542 000 actions ordinaires d'Annexon à un prix d'exercice de 3,07 $ par action, correspondant au prix de clôture du 14 février 2025.
Les options ont une durée de dix ans et deviennent acquises sur quatre ans, avec 25 % devenant acquis après la première année et le reste devenant acquis mensuellement à 1/48, sous réserve de l'emploi continu.
Annexon (ANNX) hat sechs neuen nicht-executive Mitarbeitern im Rahmen seines Beschäftigungsanreizplans 2022 Aktienoptionen gewährt. Die Aktienvergaben, die am 10. Februar 2025 genehmigt wurden, entsprechen der Nasdaq-Listing-Regel 5635(c)(4). Die Mitarbeiter erhielten Optionen zum Kauf von insgesamt 542.000 Aktien von Annexon-Stammaktien zu einem Ausübungspreis von $3,07 pro Aktie, was dem Schlusskurs vom 14. Februar 2025 entspricht.
Die Optionen haben eine Laufzeit von zehn Jahren und reifen über vier Jahre, wobei 25 % nach dem ersten Jahr reifen und der verbleibende Teil monatlich zu 1/48 reift, sofern das Beschäftigungsverhältnis fortbesteht.
- Employee retention strategy implemented through stock options, aligning employee interests with company goals
- Potential future dilution of existing shareholders through 542,000 new stock options
BRISBANE, Calif., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced that it has granted inducement to six new non-executive employees under the terms of the 2022 Employment Inducement Award Plan. The equity awards were approved on February 10, 2025, in accordance with Nasdaq Listing Rule 5635(c)(4).
In the aggregate, the new non-executive employees received options to purchase 542,000 shares of Annexon common stock. The options carry a ten-year term and an exercise price per share equal to
About Annexon
Annexon Biosciences (Nasdaq: ANNX) is developing therapeutics that stop classical complement-driven neurodegeneration as first-in-kind treatments for millions of people living with serious neuroinflammatory diseases of the body, brain and eye. Our novel scientific approach focuses on C1q, the initiating molecule of classical complement’s potent inflammatory pathway that when misdirected can lead to tissue damage and loss. By targeting C1q, our immunotherapies are designed to stop this neuroinflammatory cascade in disease before it starts. Our pipeline spans three diverse therapeutic areas – autoimmune, neurodegenerative and ophthalmic diseases – and includes targeted investigational drug candidates designed to address the unmet needs of over 8 million people worldwide. Annexon’s mission is to deliver game-changing therapies to patients so that they can live their best lives. To learn more visit annexonbio.com.
Investor Contact:
Joyce Allaire
LifeSci Advisors
jallaire@lifesciadvisors.com
FAQ
How many shares were granted in Annexon's (ANNX) February 2025 employee inducement grants?
What is the exercise price for ANNX's February 2025 employee stock options?
What is the vesting schedule for Annexon's February 2025 employee stock options?
How long is the term of ANNX's February 2025 employee stock options?
